Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BIL 010t

Next Previous
X
Search
Drug Profile

BIL 010t

Alternative Names: Anti-nf-P2X7 antibody; BIL-010t; BSCT 10% ointment

Latest Information Update: 28 Sep 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biosceptre International; Peptech UK
  • Developer Biosceptre International
  • Class Antibodies
  • Mechanism of Action Purinergic P2X7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Basal cell cancer

Highest Development Phases

  • No development reported Basal cell cancer

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for phase-I development in Basal-cell-cancer in Australia (Topical, Ointment)
  • 28 Sep 2023 No recent reports of development identified for phase-I development in Basal-cell-cancer in USA (Topical, Ointment)
  • 08 Sep 2021 BIL 010t is still in phase I trials for basal cell cancer in USA (https://www.biosceptre.com/pipeline/).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top